"Circulating Tumor DNA" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
DNA released from tumor cells that is found circulating in PLASMA; SERUM; or other BODY FLUIDS.
|Circulating Tumor DNA
- Circulating Tumor DNA
- DNA, Circulating Tumor
- Tumor DNA, Circulating
- Cell-Free Tumor DNA
- Cell Free Tumor DNA
- DNA, Cell-Free Tumor
- Tumor DNA, Cell-Free
Below are MeSH descriptors whose meaning is more general than "Circulating Tumor DNA".
Below are MeSH descriptors whose meaning is more specific than "Circulating Tumor DNA".
This graph shows the total number of publications written about "Circulating Tumor DNA" by people in this website by year, and whether "Circulating Tumor DNA" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Circulating Tumor DNA" by people in Profiles.
Contrived Materials and a Data Set for the Evaluation of Liquid Biopsy Tests: A Blood Profiling Atlas in Cancer (BLOODPAC) Community Study. J Mol Diagn. 2023 Mar; 25(3):143-155.
Tumor-Informed Approach Improved ctDNA Detection Rate in Resected Pancreatic Cancer. Int J Mol Sci. 2022 Sep 29; 23(19).
Serial circulating tumor DNA monitoring of CDK4/6 inhibitors response in metastatic breast cancer. Cancer Sci. 2022 May; 113(5):1808-1820.
The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA. Clin Cancer Res. 2022 02 15; 28(4):728-737.
Utility of Perioperative Measurement of Cell-Free DNA and Circulating Tumor DNA in Informing the Prognosis of GI Cancers: A Systematic Review. JCO Precis Oncol. 2022 02; 6:e2100337.
BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer. J Clin Oncol. 2022 02 01; 40(4):345-355.
Sensitive detection of tumor mutations from blood and its application to immunotherapy prognosis. Nat Commun. 2021 07 07; 12(1):4172.
Clinical implementation and current advancement of blood liquid biopsy in cancer. J Hum Genet. 2021 Sep; 66(9):909-926.
Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer. Chest. 2021 09; 160(3):1095-1107.
Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms. Clin Cancer Res. 2021 06 01; 27(11):3094-3105.